Tonix Pharmaceuticals Holding Corp [NASDAQ: TNXP] plunged by -$0.6 during the normal trading session on previous day and reaching a high of $35.0 during the day while it closed the day at $34.32.
Tonix Pharmaceuticals Holding Corp stock has also loss -8.99% of its value over the past 7 days. However, TNXP stock has inclined by 108.38% in the 3 months of the year. Over the past six months meanwhile, it has gained 42.70% and gained 4.06% year-on date.
The market cap for TNXP stock reached $252.50 million, with 7.36 million shares outstanding and 7.35 million shares in the current float. Compared to the average trading volume of 1.21M shares, TNXP reached a trading volume of 406379 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Tonix Pharmaceuticals Holding Corp [TNXP]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for TNXP shares is $61.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on TNXP stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Noble Capital Markets have made an estimate for Tonix Pharmaceuticals Holding Corp shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on April 18, 2022. The new note on the price target was released on April 18, 2019, representing the official price target for Tonix Pharmaceuticals Holding Corp stock. Previously, the target price had yet another raise to $6, while ROTH Capital analysts kept a Buy rating on TNXP stock.
The Average True Range (ATR) for Tonix Pharmaceuticals Holding Corp is set at 3.79, with the Price to Sales ratio for TNXP stock in the period of the last 12 months amounting to 25.15. The Price to Book ratio for the last quarter was 1.31, with the Price to Cash per share for the same quarter was set at 17.90.
TNXP stock trade performance evaluation
Tonix Pharmaceuticals Holding Corp [TNXP] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -8.99. With this latest performance, TNXP shares gained by 29.02% in over the last four-week period, additionally plugging by 42.70% over the last 6 months – not to mention a drop of -70.16% in the past year of trading.
Tonix Pharmaceuticals Holding Corp [TNXP]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Tonix Pharmaceuticals Holding Corp [TNXP] shares currently have an operating margin of -721.51% and a Gross Margin at 2.98%. Tonix Pharmaceuticals Holding Corp’s Net Margin is presently recorded at -1313.87%.
Return on Equity for this stock declined to -80.39%, with Return on Assets sitting at -80.39%.
Earnings per share (EPS) analysis for Tonix Pharmaceuticals Holding Corp [TNXP] stock
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for TNXP. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Tonix Pharmaceuticals Holding Corp go to 88.07%.
Tonix Pharmaceuticals Holding Corp [TNXP]: Institutional Ownership
There are presently around $7.03%, or 7.04%% of TNXP stock, in the hands of institutional investors. The top three institutional holders of TNXP stocks are: PRUDENTIAL FINANCIAL INC with ownership of 97707.0 shares, which is approximately 0.0239%. ALYESKA INVESTMENT GROUP, L.P., holding 62500.0 shares of the stock with an approximate value of $$43588.0 in TNXP stocks shares; and ALYESKA INVESTMENT GROUP, L.P., currently with $$39000.0 in TNXP stock with ownership which is approximately 0.0141%.
